Challenges of vaccine development include regulatory, technical, and manufacturing hurdles in translating a vaccine candidate into a commercial product.
How to successfully balance patient safety with supply-chain management
This article discusses the potential of MIS416 adjuvant, a vaccine adjuvant and immunogen co-delivery system, to provide adequate immunostimulation to overcome host factors that may limit the success of therapeutic vaccines.
Avoid manufacturing failures by effective viral inactivation.
Avoid manufacturing failures by effective viral inactivation.
There are a number of specific characteristics to be considered when developing and manufacturing live bacterial vaccines.
Supplementing your existing staff with experienced contractors when your process is ready for validation can help you avoid common validation mishaps - if you know the ingredients of successful project management.
Engaging executive leadership in the quality process is the key to compliance success.
Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Productivities similar to those achieved with stirred tanks can be achieved with disposable bioreactors.
Robust packing procedures can improve process performance and increase resin lifetime.
A simple method to leverage fermentation heat transfer data.
Despite their difficult approval pathway, biobetters offer the potential for innovation and decreased healthcare costs.
Choosing the right tools to enhance the process.
Avoid manufacturing failures by effective viral inactivation.
The author describes a methodology for developing a per product qualitative and semi-qualitative business case for applying QbD to a biopharmaceutical product.
In three non-affinity purification processes based on cation exchange capture with high binding capacity, applying a host cell protein exclusion strategy enabled robust scale up and better economics.
When platform processes are applied to fusion molecules, innovation and flexibility are needed.
The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
Effective tech transfer can save time and effort in later manufacturing processes.
Precipitation prior to capture chromatography offers a simple, robust, and economical method to remove CHO host cell proteins and DNA.
Operational planning and early cost analyses are key to generating optimal, robust, and economical commercial processes.
Can increase in ionic strength result in higher viscosity?
A simple method to leverage fermentation heat transfer data.